PER® Congress on Hematologic Malignancies (Winter Hematology®) | Conference

Dr. Cortes on Tyrosine Kinase Inhibitors in CML

February 29th 2020

Jorge E. Cortes, MD, shares his experience with tyrosine kinase inhibitors as treatment of patients with chronic myeloid leukemia.

Expanded Choices Emerge for Myelofibrosis Following Ruxolitinib Therapy

February 29th 2020

Newly approved and investigational agents are joining ruxolitinib for the treatment of myelofibrosis and may provide options for patients who progress or become intolerant to frontline JAK inhibitors.

Dr. Lonial on High-Risk Patients With Smoldering Multiple Myeloma

February 28th 2020

Sagar Lonial, MD, FACP, discusses how the treatment landscape has evolved for patients with smoldering multiple myeloma.

Park Touts Further Developments, Unmet Needs With CAR T-Cell Therapy in ALL

February 28th 2020

Jae H. Park, MD, discusses the challenges in using CAR T-cell therapy in adult patients with acute lymphoblastic leukemia, and also highlights the potential role for off-the-shelf CAR T cells.

Novel Approaches Gain Ground in Diffuse Large B-Cell Lymphoma

February 28th 2020

Despite advances made in the treatment of patients with diffuse large B-cell lymphoma, investigators are on a quest to move more novel agents through the pipeline, says Craig Moskowitz, MD, in a presentation during the 24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.

Dr. Adusumilli on the Development of CAR T Cells in Solid Tumors

February 28th 2020

Prasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.

Dr. Brody on In Situ Vaccinations for Hematologic Cancers

February 28th 2020

Joshua Brody, MD, discusses the development of in situ vaccinations, a vaccine that is created at the tumor site in patients with cancer.

Dr. Gertz on the Outlook for Waldenstrom Macroglobulinemia

March 4th 2019

Morie A. Gertz, MD, MACP, discusses the current outlook for patients with Waldenström macroglobulinemia.

Newer Agents Extend Survival and Reduce Toxicity in CLL

March 4th 2019

New agents in chronic lymphocytic leukemia are significantly strengthening the armamentarium, particularly next-generation BTK and PI3K inhibitors, and although toxicities remain an issue, tolerability may be improving.

AML Management Evolving for Elderly Patients

March 3rd 2019

More options are available than ever before for treating older patients with acute myeloid leukemia and fresh hopes are resting on combinations of venetoclax plus hypomethylating agents.

Agents Emerging in Late Relapsed/Refractory Myeloma Space

March 3rd 2019

Sagar Lonial, MD, discusses some of the emerging agents for the treatment of patients with late relapse in multiple myeloma.

Watch-and-Wait Approach Can Be Beneficial Strategy in MCL

March 3rd 2019

Prognostic indices for mantle cell lymphoma are good for classifying patients but do little in the way of guiding treatment, and often the best course of action is to watch and wait.

Chemotherapy Poised to Have Minor Role in Future CLL Treatment

March 3rd 2019

The day is approaching that chemotherapy may be unnecessary for the treatment of patients with chronic lymphocytic leukemia.

Dr. Wierda Discusses Use of CAR T Cells in CLL

March 2nd 2019

William G. Wierda, MD, PhD, discusses how CAR T cells could become more effective in the treatment of patients with chronic lymphocytic leukemia.

Jabbour Highlights Ongoing Research, Current Treatment for ALL Subtypes

March 2nd 2019

Elias Jabbour, MD, discusses the treatment options for patients with acute lymphoblastic leukemia across these various subgroups.

Dr. Usmani Discusses Management of Early Relapse in Myeloma

March 2nd 2019

Saad Z. Usmani, MD, FACP, shares his advice for the management of early relapse in patients with multiple myeloma.

Dr. Casulo on Predicting Outcomes in Follicular Lymphoma

March 2nd 2019

Carla Casulo, MD, discusses several different factors that can help predict outcomes in patients with follicular lymphoma.

Making the Case for Earlier CAR T-Cell Therapy in Lymphoma

March 2nd 2019

Real-world data on the use of chimeric antigen receptor T-cell therapy in large B-cell lymphoma bear out the pivotal results from ZUMA-1 and demonstrate not only that the treatment approach is here, but also that it’s time to address issues of efficacy, safety, cost, and moving this approach into earlier lines of therapy.

Targeted Therapies Continue to Show Promise Against FLT3, IDH1/2 Mutations in AML

March 2nd 2019

Jorge E. Cortes, MD, discusses the current treatment options for patients with acute myeloid leukemia, including the use of quizartinib in patients with FLT3 mutations, as well as data from the QuANTUM-R trial.

Dr. Daver Discusses Use of MRD Assessment in Hematologic Malignancies

March 2nd 2019

Naval G. Daver, MD, discusses the role of minimal residual disease assessment in the treatment of patients with hematologic malignancies.